Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinotherapeuticsSHSE:688247 +3.79%72 Days Payable is 41.18 as of Mar. 2026, which is 24% above its 10-year median of 33.34. GuruFocus rates SHSE:688247 with a GF Score™ of 72/100 and a GF Value™ of ¥11.40 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 926 Drug Manufacturers companies, Sinotherapeutics ranks worse than 86.5% on this metric.
The historical rank and industry rank for Sinotherapeutics's Days Payable or its related term are showing as below:
SHSE:688247'
s Days Payable Range Over the Past 10 Years
Min: 25.96 Med: 33.34 Max: 44.33
Current: 33.95
During the past 8 years, Sinotherapeutics's highest Days Payable was 44.33. The lowest was 25.96. And the median was 33.34.
SHSE:688247's Days Payable is ranked worse than 86.5% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs SHSE:688247: 33.95
Sinotherapeutics's Days Payable
increased
from Mar. 2025 (33.66) to Mar. 2026 (41.18).
It may suggest that Sinotherapeuticsdelayed paying its suppliers.
Sinotherapeutics Days Payable Related Terms
Sinotherapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Sinotherapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sinotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinotherapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sinotherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Sinotherapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sinotherapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinotherapeutics (SHSE:688247) has a Days Payable of 41.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sinotherapeutics and its competitors. This is 24% above median its historical median of 33.34. Over the past decade, Sinotherapeutics' Days Payable has ranged from 25.96 to 44.33. According to the industry distribution chart, Sinotherapeutics ranks #801 out of 926 companies in the Drug Manufacturers industry, placing it in the top 86.5%.
Is Sinotherapeutics' Days Payable too high?
Sinotherapeutics' current Days Payable of 41.18 is 24% above median its 10-year median of 33.34. Over the past 10 years, this metric has ranged from a low of 25.96 to a high of 44.33. The Drug Manufacturers industry median Days Payable is 90.22. Sinotherapeutics' value of 41.18 is 54.4% below this industry median. Based on the distribution chart, Sinotherapeutics ranks #801 out of 926 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sinotherapeutics has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinotherapeutics' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sinotherapeutics ranks #801 out of 926 companies for Days Payable. This places Sinotherapeutics in the lower half of its industry. The industry median Days Payable is 90.22. Sinotherapeutics' value of 41.18 is 54.4% below this benchmark. Historically, Sinotherapeutics' own Days Payable has ranged from 25.96 to 44.33 over the past decade. While the company's 10-year median is 33.34 vs. the industry median of 90.22, Sinotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinotherapeutics's current Days Payable of 41.18 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sinotherapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinotherapeutics's current Days Payable is 41.18, which is 24% above median its own 10-year median of 33.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sinotherapeutics (SHSE:688247) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥11.40, compared to a current price of ¥8.48 — trading 25.6% below its estimated fair value. The current Days Payable is 41.18, which is 24% above median its 10-year median of 33.34 and 54.4% below the Drug Manufacturers industry median of 90.22. Sinotherapeutics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sinotherapeutics (SHSE:688247), the current Days Payable is 41.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinotherapeutics (SHSE:688247) Overvalued in 2026?
Based on GuruFocus' analysis, Sinotherapeutics stock appears to be undervalued.
The current stock price of ¥8.48 is trading 25.6% below its estimated GF Value™ of ¥11.40.
GuruFocus considers Sinotherapeutics to be Modestly Undervalued.
Key valuation signals for SHSE:688247:
Days Payable: 41.18 (24% above median its 10-year median of 33.34)
GF Value™: ¥11.40 vs. price of ¥8.48 (25.6% below fair value)
Industry Position: 54.4% below the Drug Manufacturers median (#801 of 926)
No single metric tells the full story. See the SHSE:688247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688247 has been successfully added to your 
